Document is current
Any future updates will be listed below
-
Authors
Buckup, Mark https://orcid.org/0000-0001-6938-3474
Figueiredo, Igor
Ioannou, Giorgio https://orcid.org/0000-0001-7956-7605
Ozbey, Sinem
Cabal, Rafael
Tabachnikova, Alexandra
Troncoso, Leanna https://orcid.org/0000-0003-2529-9267
Le Berichel, Jessica
Zhao, Zhen
Ward, Stephen C.
Hennequin, Clotilde
Akturk, Guray https://orcid.org/0000-0001-7032-8085
Hamel, Steve
Fiel, Maria Isabel
Brody, Rachel
Schwartz, Myron https://orcid.org/0000-0002-9113-886X
Marron, Thomas U. https://orcid.org/0000-0001-5903-8191
Kim-Schulze, Seunghee https://orcid.org/0000-0003-0192-4400
Roudko, Vladimir
Gonzalez-Kozlova, Edgar
Hamon, Pauline https://orcid.org/0000-0002-6776-1635
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA224319, P30CA196521, R33CA263705, CA257195, CA254104, CA154947)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (U01DK124165)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR004419)
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 30 June 2025
First Online: 25 August 2025
Competing interests
: M.M. serves on the scientific advisory board and holds stock from Compugen, Dynavax, Morphic Therapeutic, Asher Bio, Dren Bio, Nirogy, Oncoresponse and Owkin. M.M. serves on the scientific advisory board of Innate Pharma, DBV and Genenta. M.M. receives funding for contracted research from Regeneron and Boehringer Ingelheim. T.U.M. has served on advisory and/or data safety monitoring boards for Rockefeller University, Regeneron Pharmaceuticals, Abbvie, Bristol Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus and Astellas, and has research grants from Regeneron, Bristol Myers Squibb, Merck and Boehringer Ingelheim. S.G. reports past consultancy or advisory roles for Merck and OncoMed; research funding from Regeneron Pharmaceuticals related to this study, and research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono, Pfizer and Takeda, unrelated to the current work. S.G. is a named co-inventor on an issued patent (US20190120845A1) for multiplex immunohistochemistry to characterize tumours and treatment responses. The technology is filed through Icahn School of Medicine at Mount Sinai and is currently unlicensed. This technology was used to evaluate tissue in this study and the results could impact the value of this technology.
